Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
80,797,753
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
26,479,657
-
Shares change
-
+3,675,751
-
Total reported value, excl. options
-
$1,284,263,574
-
Value change
-
+$188,105,374
-
Number of buys
-
80
-
Number of sells
-
-39
-
Price
-
$48.5
Significant Holders of Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) as of Q2 2021
135 filings reported holding KYMR - Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2021.
Kymera Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KYMR) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26,479,657 shares
of 80,797,753 outstanding shares and own 32.77% of the company stock.
Largest 10 shareholders include BVF INC/IL (2,630,658 shares), Redmile Group, LLC (2,531,508 shares), BlackRock Inc. (2,448,517 shares), FMR LLC (2,182,429 shares), VANGUARD GROUP INC (2,044,224 shares), BAKER BROS. ADVISORS LP (1,959,211 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,844,926 shares), STATE STREET CORP (1,336,646 shares), Deer IX & Co. Ltd. (1,235,308 shares), and WELLINGTON MANAGEMENT GROUP LLP (827,941 shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.